GoodRx Holdings (GDRX) has posted Q1 2026 revenue of US$194.0 million with basic EPS of about US$0.00, alongside trailing twelve month revenue of US$787.9 million and basic EPS of US$0.06. This gives investors a clear read on both the latest quarter and the broader run rate. Over the past year, the company has seen quarterly revenue move between US$194.0 million and US$203.1 million, while basic EPS has ranged from roughly US$0.00 to US$0.04, so the Q1 print slots into a period where earnings have been positive but thin. With trailing net profit margins at 2.6% versus 3.6% a year earlier and a one off US$18.7 million loss weighing on headline figures, this update keeps the focus squarely on how efficiently the business can convert its revenue base into more durable margins.

See our full analysis for GoodRx Holdings.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the prevailing GoodRx narratives, and where the data backs or challenges what investors have been telling themselves about the stock.

Margins Thin At 2.6% Trailing Level

• Over the last 12 months, GoodRx generated US$787.9 million in revenue and US$20.6 million in net income, which works out to a 2.6% net margin compared with 3.6% a year earlier. Q1 2026 net income of US$1.2 million and EPS of about US$0.00 sit within that slim profitability profile.
• What stands out for the bullish narrative is that analysts are looking for earnings to grow about 26.2% per year while revenue is forecast at around 4.2% a year. This puts a lot of weight on margin improvement, even though the trailing 2.6% margin is lower than last year and includes a US$18.7 million one off loss that pulled profits down.
  • Bulls highlight opportunities such as higher margin subscription services and pharma manufacturer solutions. However, the latest four reported quarters show net income between US$1.1 million and US$34.6 million, so the recent margin compression and one off loss need to be reconciled with that earnings growth story.
  • Supporters of the bullish view may point to the Q1 2026 profit, but with Basic EPS moving between about US$0.00 and US$0.04 over the last five quarters, the current figures still leave limited room for error if those higher forecast margins take time to show up.

Bulls argue that today’s thin margins could be a starting point for much faster earnings growth, not a ceiling. If that angle interests you it is worth seeing how the optimistic thesis is built out in detail in the 🐂 GoodRx Holdings Bull Case

Premium P/E Against Peers And Industry

• The stock trades on a P/E of 47.3x, above its peer average of 43.9x and well above the Global Healthcare Services industry at 28.4x, even though trailing net income over the last year was US$20.6 million on US$787.9 million of revenue.
• Critics highlight that this elevated P/E sits alongside a major risk: interest payments that are not well covered by earnings. The bearish narrative questions whether the current valuation properly reflects financial leverage pressure when margins are at 2.6% and share price volatility has already shown up over the past three months.
  • Bears point to the combination of thin profits and higher multiple, arguing that if earnings stay close to recent quarterly levels, the valuation leaves little cushion, particularly when compared with the industry’s lower 28.4x P/E.
  • The fact that analysts’ forecasts still imply about 26.2% EPS growth per year is key for that multiple, and any disappointment relative to the recent US$1.2 million quarterly net income run rate could be felt quickly in a higher P/E stock.

Skeptics see the high P/E and weak interest coverage as a warning sign, so it can be useful to walk through their full argument in the 🐻 GoodRx Holdings Bear Case

DCF Fair Value Far Above US$2.84 Price

• The shares trade at about US$2.84 while a DCF fair value of roughly US$10.11 is presented, implying the stock is assessed as trading well below that model based estimate even though trailing EPS is only about US$0.06.
• Consensus narrative highlights this valuation gap alongside moderate forecast revenue growth of about 2.8% to 4.2% a year and rising margins from 3.8% to a projected 5.8%. Yet the latest trailing numbers of US$787.9 million revenue and US$20.6 million net income, plus the US$18.7 million one off loss, show that the path from today’s low profitability to that higher DCF fair value relies heavily on those margin assumptions.
  • Supporters of the consensus view might point out that analysts’ target price of about US$2.88 is close to where the stock currently trades, even though the DCF fair value is much higher. This frames today’s price as roughly in line with that target but far from the cash flow based estimate.
  • At the same time, the recent pattern of quarterly net income between roughly US$1.1 million and US$12.8 million over the last five reported quarters suggests the business has not yet reached the earnings level implied by those longer term forecasts.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for GoodRx Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals on margins, valuation and sentiment running through this update, it makes sense to check the underlying data yourself and decide how comfortable you are with the balance of risk and reward. You can start with the 2 key rewards and 3 important warning signs.

Explore Alternatives

GoodRx is working with thin 2.6% margins, modest net income and weak interest coverage, while trading on a higher P/E than peers and its industry.

If that mix of tight profitability and balance sheet pressure makes you uneasy, take a few minutes to size up companies in the solid balance sheet and fundamentals stocks screener (45 results) and compare their financial strength side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.